| Literature DB >> 34345381 |
Seyedeh Somayeh Hosseini1, Khosrow Aghaiypour Kolyani2, Robab Rafiei Tabatabaei3, Hossein Goudarzi4, Abbas Akhavan Sepahi5, Maryam Salemi2.
Abstract
Newcastle disease (ND) is known as the most common diseases of economic importance worldwide. Vaccination against virulent strains of Newcastle disease virus (NDV) has failed during some outbreaks. Here, we aimed to assess the epitopes of NDV fusion protein as targets for a peptide-based vaccine. To explore the most antigenic epitopes on the F protein, we retrieved virulent strains of genotype VII from National Center for Biotechnology Information (NCBI). Linear and conformational B-cell epitopes were identified. Moreover, T-cell epitopes with high and moderate binding affinities to human major histocompatibility complex (MHC) class I and class II alleles were predicted using bioinformatics tools. Subsequently, the overlapped epitopes of B-cell and MHC class I and MHC class II were determined. To validate our predictions, the best epitopes were docked, to chicken MHC class I (B-F) alleles using the HADDOCK flexible docking server. Seven 'high ranked epitopes' were identified. Among them, 'LYCTRIVTF' and 'MRATYLETL' showed the highest scores. The other five epitopes including LSGEFDATY, LTTPPYMALK, LYLTELTTV, DCIKITQQV and SIAATNEAV obtained very encouraging results as well. SIAATNEAV had been recognized as a neutralizing epitope of F protein using monoclonal antibodies before. Taken together, our results demonstrated that the identified epitopes needed to be tested by in vitro and in vivo experiments.Entities:
Keywords: Docking; Epitope; Newcastle disease virus; Peptide-based vaccine
Year: 2021 PMID: 34345381 PMCID: PMC8328245 DOI: 10.30466/vrf.2019.98625.2351
Source DB: PubMed Journal: Vet Res Forum ISSN: 2008-8140 Impact factor: 1.054
Protective linear B-cell epitopes of F protein identified by BepiPred, BCpreds and ElliPro
|
|
|
|
|
|
|---|---|---|---|---|
|
| 1 | 288-297 | NLPSVGNLNN | 0.84 |
| 2 | 307-318 | SVSTTKGYASAL | 0.54 | |
| 3 | 328-334 | SVIEELD | 0.64 | |
| 4 | 354-360 | PMSPGIY | 0.87 | |
| 5 | 439-446 | EFDATYQK | 1.13 | |
| 6 | 461-477 | LDISTELGNVNNSISNA | 0.73 | |
|
| 1 | 180-199 | GKMQQFVNDQFNNTARELDC | 0.50 |
| 2 | 214-233 | LTELTTVFGPQITSPALTQL | 0.45 | |
| 3 | 308-327 | VSTTKGYASALVPKVVTQVG | 0.54 | |
| 4 | 366-385 | NTSACMYSKTEGALTTPYMA | 0.46 | |
|
| 1 | 186-211 | VNDQFNNTARELDCIKITQQVGVELN | 1.04 |
| 2 | 308-314 | VSTTKGY | 0.86 |
Conformational B cell epitopes of F protein (CBTOPE, ElliPro).
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| 1 | 72 | 81 |
| 10 | |
| 2 | 153 | 200 |
| 48 | ||
| 3 | 230 | 231 |
| 2 | ||
| 4 | 284 | 286 |
| 3 | ||
| 5 | 296 | 305 |
| 10 | ||
| 6 | 342 | 381 |
| 40 | ||
| 7 | 445 | 455 |
| 11 | ||
| 8 | 463 | 463 |
| 1 | ||
| 9 | 523 | 523 |
| 1 | ||
|
| 1 | A:N476, A:D479, A:K480, A:A482, A:E483, A:S484, A:N485, A:S486, A:K487, A:L488, A:E489, A:K490, A:V491, A:N492, A:V493, A:R494, A:L495, A:496, A:S497, A:T498, A:S499, A:A500, A:L501, A:I502, A:T503, A:Y504, A:I505, A:V506, A:L507, A:T508, A:V509, A:I510, A:S511, A:L512, A:V513, A:F514, A:G515, A:A516, A:L517, A:S518, A:L519, A:G520, A:L521, A:A522, A:C523, A:Y524, A:L525, A:M526, A:Y527, A:K528, A:Q529, A:K530, A:A531, A:Q532, A:Q533, A:K534, A:T535, A:L536, A:L537, A:W538, A:L539, A:G540, A:N541, A:N542, A:T543, A:L544, A:D545, A:Q546, A:M547, A:R548, A:A549, A:T550, A:T551, A:R552, A:A553 | 75 | 0.874 | ||
| 2 | A:A39, A:L306, A:S307, A:V308, A:S309, A:T310, A:T311, A:K312, A:G313, A:Y314, A:E376, A:G377, A:A378, A:L379, A:T380, A:T381, A:P382, A:Y383, A:M384, A:A385, A:L386, A:K387, A:G388, A:S389, A:V390, A:I391, A:A392, A:N393, A:C394, A:K395, A:I396, A:T397, A:T398, A:C399, A:R400, A:C401, A:T402, A:D403, A:P404, A:P405, A:G406, A:I407, A:I408, A:S409, A:Q410, A:N411, A:Y412, A:G413, A:E414, A:A415, A:V416, A:S417, A:L418, A:I419, A:D420, A:R421, A:H422, A:S423, A:C424, A:N425, A:V426, A:L427, A:S428, A:L429, A:D430, A:G431, A:I432, A:T433, A:L434, A:R435, A:L436, A:S437, A:G438, A:E439, A:F440, A:D441, A:A442, A:T443, A:Y444, A:Q445, A:K446, A:N447, A:I448 | 83 | 0.70 | |||
Molecular docking of control peptides with BF2*2101 and BF2*0401
|
|
|
|
|
|
|---|---|---|---|---|
|
|
| 1 | −94.30 ± 5.50 | 10 |
|
| 2 | 105.80 ± 6.50 | 8 | |
|
| 1 | 80.50 ± 2.60 | 5 | |
|
| 1 | 95.00 ± 4.40 | 5 | |
|
| 2 | 105.80 ± 6.50 | 10 | |
|
| 1 | 95.80 ± 1.90 | 4 | |
|
| 1 | 93.10 ± 2.60 | 9 | |
|
| 2 | 114.50 ± 4.20 | 4 | |
|
|
| 1 | 107.60 ± 7.50 | 9 |
|
| 1 | 119.40 ± 2.70 | 10 | |
|
| 2 | 91.60 ± 4.70 | 7 | |
|
| 1 | 83.00 ± 1.90 | 6 | |
|
| 1 | 97.00 ± 2.90 | 11 | |
|
| 1 | 104.60 ± 1.10 | 6 | |
|
| 1 | 101.00 ± 7.10 | 10 | |
|
| 1 | 117.70 ± 2.60 | 8 |
Molecular docking of epitopes with BF2*2101, BF2*0401
|
|
|
|
|
|
|---|---|---|---|---|
|
| BF2*2101 (3BEW) | 1 | −126.90 ± 8.00 | 5 |
|
| 3 | 96.20 ± 5.600 | 7 | |
|
| 1 | 107.10 ± 3.60 | 10 | |
|
| 2 | 88.90 ± 5.90 | 6 | |
|
| 2 | 102.20 ± 6.70 | 10 | |
|
| 1 | 125.60 ± 2.90 | 11 | |
|
| 1 | 130.60 ± 8.10 | 8 | |
|
| 2 | 95.20 ± 5.60 | 9 | |
|
| 2 | 103.20 ± 3.9 | 11 | |
|
| 1 | 101.60 ± 3.90 | 7 | |
|
| 2 | 87.90 ± 6.50 | 7 | |
|
| 3 | 93.80 ± 10.30 | 15 | |
|
| 1 | 86.40 ± 2.20 | 4 | |
|
| BF2*0401 (4G42) | 1 | 115.10 ± 3.90 | 9 |
|
| 1 | 117.80 ± 3.9 | 10 | |
|
| 1 | 98.50 ± 5.90 | 10 | |
|
| 1 | 100.00 ± 1.80 | 7 | |
|
| 1 | 96.60 ± 3.30 | 10 | |
|
| 1 | 114.60 ± 5.00 | 11 | |
|
| 1 | 124.40 ± 5.50 | 7 | |
|
| 1 | 102.70 ± 3.70 | 11 | |
|
| 2 | 92.40 ± 2.00 | 9 | |
|
| 1 | 1020 ± 7.10 | 13 | |
|
| 1 | 85.40 ± 1.00 | 9 | |
|
| 1 | 95.10 ± 0.40 | 12 | |
|
| 1 | 105.60 ± 5.00 | 14 |
Fig. 1The predicted epitopes of NDV fusion protein docked to BF2*0401 and BF2*2101. A) LSGEFDATY-BF2*0401 complex, B) LYLTELTTV-BF2*0401 complex, C) MRATYLETL-BF2*2101 complex, and D) LYCTRIVTF-BF2*2101 complex